151 related articles for article (PubMed ID: 12481303)
1. 4-Hydroxytamoxifen sulfation metabolism.
Chen G; Yin S; Maiti S; Shao X
J Biochem Mol Toxicol; 2002; 16(6):279-85. PubMed ID: 12481303
[TBL] [Abstract][Full Text] [Related]
2. Alpha-hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts.
Shibutani S; Dasaradhi L; Terashima I; Banoglu E; Duffel MW
Cancer Res; 1998 Feb; 58(4):647-53. PubMed ID: 9485016
[TBL] [Abstract][Full Text] [Related]
3. Interactions of the stereoisomers of alpha-hydroxytamoxifen with human hydroxysteroid sulfotransferase SULT2A1 and rat hydroxysteroid sulfotransferase STa.
Apak TI; Duffel MW
Drug Metab Dispos; 2004 Dec; 32(12):1501-8. PubMed ID: 15371299
[TBL] [Abstract][Full Text] [Related]
4. Formation of tamoxifen-DNA adducts via O-sulfonation, not O-acetylation, of alpha-hydroxytamoxifen in rat and human livers.
Kim SY; Laxmi YR; Suzuki N; Ogura K; Watabe T; Duffel MW; Shibutani S
Drug Metab Dispos; 2005 Nov; 33(11):1673-8. PubMed ID: 16099924
[TBL] [Abstract][Full Text] [Related]
5. Sulfation of alpha-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen-DNA adducts.
Shibutani S; Shaw PM; Suzuki N; Dasaradhi L; Duffel MW; Terashima I
Carcinogenesis; 1998 Nov; 19(11):2007-11. PubMed ID: 9855017
[TBL] [Abstract][Full Text] [Related]
6. Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases.
Falany JL; Pilloff DE; Leyh TS; Falany CN
Drug Metab Dispos; 2006 Mar; 34(3):361-8. PubMed ID: 16381672
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen induction of aryl sulfotransferase and hydroxysteroid sulfotransferase in male and female rat liver and intestine.
Maiti S; Chen G
Drug Metab Dispos; 2003 May; 31(5):637-44. PubMed ID: 12695353
[TBL] [Abstract][Full Text] [Related]
8. Organ specificity of DNA adduct formation by tamoxifen and alpha-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment.
Phillips DH; Hewer A; Osborne MR; Cole KJ; Churchill C; Arlt VM
Mutagenesis; 2005 Jul; 20(4):297-303. PubMed ID: 15928012
[TBL] [Abstract][Full Text] [Related]
9. Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of alpha-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts.
Boocock DJ; Maggs JL; Brown K; White IN; Park BK
Carcinogenesis; 2000 Oct; 21(10):1851-8. PubMed ID: 11023543
[TBL] [Abstract][Full Text] [Related]
10. Evidence that the catechol 3,4-Dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins.
Dehal SS; Kupfer D
Cancer Res; 1996 Mar; 56(6):1283-90. PubMed ID: 8640815
[TBL] [Abstract][Full Text] [Related]
11. Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases.
Nishiyama T; Ogura K; Nakano H; Ohnuma T; Kaku T; Hiratsuka A; Muro K; Watabe T
Biochem Pharmacol; 2002 May; 63(10):1817-30. PubMed ID: 12034366
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of lower genotoxicity of toremifene compared with tamoxifen.
Shibutani S; Ravindernath A; Terashima I; Suzuki N; Laxmi YR; Kanno Y; Suzuki M; Apak TI; Sheng JJ; Duffel MW
Cancer Res; 2001 May; 61(10):3925-31. PubMed ID: 11358807
[TBL] [Abstract][Full Text] [Related]
13. Formation of tamoxifen-DNA adducts in human endometrial explants exposed to alpha-hydroxytamoxifen.
Kim SY; Suzuki N; Laxmi YR; McGarrigle BP; Olson JR; Sharma M; Sharma M; Shibutani S
Chem Res Toxicol; 2005 May; 18(5):889-95. PubMed ID: 15892583
[TBL] [Abstract][Full Text] [Related]
14. Sex differences in the activation of tamoxifen to DNA binding species in rat liver in vivo and in rat hepatocytes in vitro: role of sulfotransferase induction.
Davis W; Hewer A; Rajkowski KM; Meinl W; Glatt H; Phillips DH
Cancer Res; 2000 Jun; 60(11):2887-91. PubMed ID: 10850433
[TBL] [Abstract][Full Text] [Related]
15. Rat, but not human, sulfotransferase activates a tamoxifen metabolite to produce DNA adducts and gene mutations in bacteria and mammalian cells in culture.
Glatt H; Davis W; Meinl W; Hermersdörfer H; Venitt S; Phillips DH
Carcinogenesis; 1998 Oct; 19(10):1709-13. PubMed ID: 9806149
[TBL] [Abstract][Full Text] [Related]
16. The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy.
Dehal SS; Brodie AM; Kupfer D
Drug Metab Dispos; 1999 Mar; 27(3):389-94. PubMed ID: 10064571
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen: evidence by 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite.
Randerath K; Moorthy B; Mabon N; Sriram P
Carcinogenesis; 1994 Oct; 15(10):2087-94. PubMed ID: 7955037
[TBL] [Abstract][Full Text] [Related]
18. Sulfation of tibolone and tibolone metabolites by expressed human cytosolic sulfotransferases.
Falany JL; Macrina N; Falany CN
J Steroid Biochem Mol Biol; 2004 Apr; 88(4-5):383-91. PubMed ID: 15145448
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen-DNA adduct formation in rat liver determined by immunoassay and 32P-postlabeling.
Divi RL; Osborne MR; Hewer A; Phillips DH; Poirier MC
Cancer Res; 1999 Oct; 59(19):4829-33. PubMed ID: 10519392
[TBL] [Abstract][Full Text] [Related]
20. 2-Acetylaminofluorene-mediated alteration in the level of liver arylsulfotransferase IV during rat hepatocarcinogenesis.
Ringer DP; Norton TR; Howell BA
Cancer Res; 1990 Sep; 50(17):5301-7. PubMed ID: 2386938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
